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TLCK (N-cc-tosyl-L-Iysine chloromethyl ketone) inhibits protei? kinase C whether or not the enzyme is 
under the regulation of Ca2+ and phospholipid. TLCK (IC,= 1 mM) is a much more potent inhibitor of 
protein kinase C than TPCK (N-a-tosyl-L-phenylalanine chloromethyl ketone) (IC,= 8 mM), suggesting 
that the iysyl moiety of TLCK may be specifically recognized by the active site of protein kinase C. These 
results extend the evidence that the active site of protein kinase C recognizes basic amino acids, and suggest 
that the active sites of protein kinase C and the CAMP-dependent protein kinase, which is also inhibited 
by TLCK and TPCK, are structurally related. 
Protein kinase C Tumor promotion Protease inhibitor 
1. INTRODUCTION 
Protein kinase C is a Ca2”- and phospholipid- 
dependent protein kinase which catalyzes the 
phosphorylation of proteins on serine and 
threonine residues [I]. Recent studies have sug- 
gested a role for this enzyme in the mechanism of 
action of several growth factors and hormones [2], 
since certain growth factors and hormones cause 
the formation of diacylglycerides in responsive 
cells by stimulating phosphatidylinositol metabo- 
lism, and PKC is activated by diacylglycerides [3]. 
PKC is also activated by tumor promoters, in- 
cluding several phorbol esters [4] as well as the in- 
dole alkaloid teleocidin and the polyacetate aply- 
siatoxin [5]. In addition, the enzyme co-purifies to 
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tetradecanoyl-phorbol 13-acetate; TLCK, Na-tosyl-L- 
Iysine chIoromethy1 ketone; TPCK, N-cr-tosyf-L- 
phenyIaIanine ~hloromethyI ketone; DMSO, dimethyl 
sulfoxide; PMSF, phenylmethylsulfony1 fluoride 
homogeneity with the high affinity phorboI ester 
receptor [6]. Thus it appears that this enzyme plays 
a critical role in tumor promotion. 
2. MATERIALS AND METHODS 
[y-32P]ATP was obtained from Amersham. 
Histone III-S, phosphatidylserine, TLCK, TPCR, 
Tris-HCl, PMSF, soybean trypsin inhibitor (type 
l-S), antipain, and DEAE-Sephacel were from 
Sigma. Phosphocellulose paper grade P81 was 
from Whatman, and leupeptin was a gift of the 
US-Japan Cooperative Cancer Research Program. 
Bowman-Birk inhibitor was a gift from Dr 
Jonathan Yavelow. 
PKC was partially purified from rat brain ac- 
cording to a published procedure [7]+ The enzyme 
was assayed by measuring the phosphotransferase 
reaction between [T-~~P]ATP and histone III-S 
(lysine rich fraction) in the presence of Ca2+ and 
phosphatidylserine, as described [7]. Reaction mix- 
tures contained either TLCK or TPCK at the 
designated concentrations. Both TLCK and TPCK 
were preincubated with PKC for 10 min at 30°C 
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prior to their addition to the reaction mixture. All 
reactions were initiated by the addition of enzyme 
and incubated at pH 7.5 and 30°C for 10 min. 
Reactions were terminated on phosphocellulose 
paper as described [7]. All assays were done in 
triplicate, and the data are expressed as mean 
values, with the variations of replicates indicated. 
3. RESULTS 
Fig.1 indicates the effects of increasing concen- 
trations of TLCK and TPCK on PKC activity in a 
standard assay done in the presence of Ca2+ and 
phosphatidylserine. TLCK was considerably more 
potent than TPCK in the inhibition of PKC; their 
1Cs0 values were approx. 1 and 8 mM, respectively 
(fig.1). Greater than 90% inhibition was obtained 
inhibitor Concentration (mM) 
Fig.1. Effects of TLCK and TPCK on PKC activity 
using histone III-S as the substrate. Rat brain PKC was 
assayed as described in section 2. An aqueous solution of 
TLCK was preincubated with PKC for 10 min prior to 
the phosphotransferase r action. TPCK was dissolved in 
DMSO, and was also preincubated for IO min with 
PKC. The final concentration of DMSO in the TPCK 
reaction mixture was 8%. Control studies indicated that 
this concentration of DMSO did not affect PKC activity. 
Each data point represents triplicate determinations. 
Duplicate experiments gave similar results. % inhibition 
represents [ 1 - (Ca”- and phospholipid-dependent 
histone phosphorylation observed in the presence of 
inhibitor divided by Ca2+- and phospholipid-dependent 
histone phosphorylation observed in the absence of 
inhibitor)] x 100. (A) Inhibition by TLCK; (D) 
II 10 I I I I i I I 
0 I 2 3 4 5 6 7 8 910 * 
Inhibitor Concentration (mM) 
Fig.2. Effects of TLCK on PKC activity using protamine 
sulfate as the substrate. Rat brain PKC was assayed as 
described in section 2 except protamine sulfate 
(0.67 mg/ml) was added rather than histone III-S. 
Vo inhibition represents [ 1 - (protamine sulfate 
phosphorylation observed in the presence of TLCK 
divided by protamine sulfate phosphorylation observed 
inhibition by TPCK. in the absence of TLCK)] x 100. 
at higher concentrations with each compound. 
Time course studies employing 5 mM TLCK and 
10 mM TPCK indicated that maximal inhibition 
with each of these compounds was achieved within 
10 min at 30°C after the addition of the compound 
(not shown). Therefore, in all of the studies 
described here, the enzyme was preincubated with 
the inhibitor for 10 min at 30°C prior to the addi- 
tion of the other components of the reaction 
mixture. 
To obtain further information concerning the 
mechanism of the inhibition of PKC by TLCK, we 
tested the effects of TLCK on PKC activity using 
protamine sulfate rather than histone III-S as the 
phosphoacceptor substrate. The phosphorylation 
of protamine sulfate which is catalyzed by PKC oc- 
curs in a Ca’+- and phospholipid-independent 
manner [l]. Fig.2 indicates that TLCK is an effec- 
tive inhibitor of PKC-mediated phosphorylation 
of protamine sulfate in reactions carried out in the 
absence of added Ca*+ or phospholipid, with an 
IC~O value of about 0.25 mM. These results suggest 
that TLCK interacts directly with the active site of 
PKC rather than with the phospholipid cofactor or 
a regulatory domain on the enzyme. 
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Several studies indicate that the tumor pro- 
moting effects of TPA during two stage car- 
cinogenesis on mouse skin can be inhibited by cer- 
tain protease inhibitors, including TLCK and 
TPCK [8]. Therefore, we tested some of these 
compounds, including the Bowman-Birk inhibitor 
[9] for inhibition of PKC activity in the presence of 
Ca2’ and phospholipid, using histone III-S as the 
substrate. Leupeptin (4.2 mM), antipain (5 mM), 
the Bowman-Birk inhibitor (0.2 mM), soybean 
trypsin inhibitor (0.2 mM) and PMSF (1 mM) fail- 
ed to produce detectable inhibition of PKC under 
the assay conditions described in section 2, in 
which millimolar concentrations of TLCK were in- 
hibitory, providing evidence that the in vitro in- 
hibition of PKC by TLCK and TPCK is not 
mediated by contaminating proteases. 
4. DISCUSSION 
Previous studies from this laboratory using syn- 
thetic oligopeptides as substrates for PKC suggest 
that the active site of PKC recognizes basic amino 
acids that flank the amino terminal side of the 
phosphoaccecptor residue in substrate proteins [7]. 
The structures of known PKC protein substrates 
are consistent with this hypothesis. HMG 17 
protein is phosphorylated by PKC at Ser 24 
in the sequence Gln-Arg-Arg-Ser 24-Ala-Arg-Leu- 
Ser 2%Ala-Lys [lo], the EGF receptor is 
phosphorylated by PKC at Thr 654 of the sequence 
Val-Arg-Lys-Arg-Thr 654-Leu-Arg-Arg [ 111, and 
histone Hl is phosphorylated by PKC at Ser 38 in 
the sequence Arg-Arg-Lys-Ala-Ser 38-Gly-Pro- 
Pro-Val [ 121. The data presented here indicate that 
TLCK is a more potent PKC inhibitor than TPCK, 
suggesting that the basic moiety of TLCK may be 
specifically recognized by the active site of the 
kinase. We have previously reported that the 
CAMP-dependent protein kinase and PKC can 
catalyze the phosphorylation of closely related se- 
quences [7]. The results presented here concerning 
the inhibition of PKC by TLCK and TPCK extend 
the evidence that the phosphoacceptor substrate 
binding sites of the CAMP-dependent protein 
kinase and PKC are structurally related, since the 
catalytic subunit of the CAMP-dependent protein 
kinase is also inhibited by TLCK and TPCK [ 131. 
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Our results with TLCK and TPCK suggest hat a 
potent PKC inhibitor can be developed by ex- 
ploiting active site groups of PKC which recognize 
phosphoacceptor substrates. Such inhibitors could 
be extremely valuable for further elucidating the 
mechanism of action of PKC and the role of this 
enzyme in hormone action, growth control and 
tumor promotion. 
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